112 related articles for article (PubMed ID: 21225238)
1. [Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].
Leitner AA; Hehlmann R
Internist (Berl); 2011 Feb; 52(2):209-17. PubMed ID: 21225238
[TBL] [Abstract][Full Text] [Related]
2. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
Agrawal M; Garg RJ; Kantarjian H; Cortes J
Curr Oncol Rep; 2010 Sep; 12(5):302-13. PubMed ID: 20640942
[TBL] [Abstract][Full Text] [Related]
4. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Champlin R; Jabbour E; Kebriaei P; Anderlini P; Andersson B; de Lima M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S96-100. PubMed ID: 22035758
[TBL] [Abstract][Full Text] [Related]
7. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
8. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Tinsley SM
J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830
[TBL] [Abstract][Full Text] [Related]
9. Stem cell transplant for chronic myeloid leukemia in the imatinib era.
Radich J
Semin Hematol; 2010 Oct; 47(4):354-61. PubMed ID: 20875552
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
13. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).
Klyuchnikov E; Kröger N; Brummendorf TH; Wiedemann B; Zander AR; Bacher U
Biol Blood Marrow Transplant; 2010 Mar; 16(3):301-10. PubMed ID: 19744571
[TBL] [Abstract][Full Text] [Related]
14. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
15. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
16. Selecting the best frontline treatment in chronic myeloid leukemia.
Yilmaz M; Abaza Y; Jabbour E
Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era.
Russo D; Malagola M; Skert C; Filì C; Bergonzi C; Cancelli V; Cattina F
Curr Cancer Drug Targets; 2013 Sep; 13(7):755-67. PubMed ID: 23941515
[TBL] [Abstract][Full Text] [Related]
18. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
19. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
20. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]